I think there is a valid short opportunity here.
Here is more fundamental analysis (done by ChatGPT).
///////////////////////////////////////////////////////////////////////////////
Ibnsina Pharma is a prominent pharmaceutical distribution company in Egypt, listed on the Egyptian Exchange under the ticker symbol ISPH. Established in 2001, the company distributes a wide range of pharmaceutical and cosmetic products to both private and public-sector clients, including pharmacies, hospitals, and healthcare institutions.
INVESTING.COM
Financial Overview:
Revenue: In 2023, Ibnsina Pharma reported revenues of approximately EGP 33.95 billion.
BARRONS.COM
Net Income: The net income for the same period was EGP 173.14 million, resulting in a net profit margin of 0.51%.
BARRONS.COM
Total Assets and Liabilities: The company's total assets stood at EGP 18.55 billion, with total liabilities amounting to EGP 17.1 billion, indicating a debt-to-assets ratio of 92.19%.
BARRONS.COM
Shareholder Structure:
Ibnsina Pharma's ownership is diversified among prominent entities:
Free Float: 40.7%
Abdel Gawad Family: 15.0%
Faisal Islamic Bank: 14.0%
Mahgoub Family: 12.9%
European Bank for Reconstruction and Development (EBRD): 9.6%
Blom Investment: 7.8%
This diverse shareholder base has enhanced the company's corporate governance practices.
IR.IBNSINA-PHARMA.COM
Stock Performance:
As of January 29, 2025, the stock closed at EGP 7.02 per share, with a 52-week range between EGP 2.14 and EGP 7.59.
IR.IBNSINA-PHARMA.COM
Considerations for Investors:
While Ibnsina Pharma has demonstrated significant revenue generation, its net profit margin is relatively low, and the company operates with a high debt-to-assets ratio. Potential investors should weigh these factors carefully and consider consulting with a financial advisor to determine if this investment aligns with their risk tolerance and financial objectives.
Here is more fundamental analysis (done by ChatGPT).
///////////////////////////////////////////////////////////////////////////////
Ibnsina Pharma is a prominent pharmaceutical distribution company in Egypt, listed on the Egyptian Exchange under the ticker symbol ISPH. Established in 2001, the company distributes a wide range of pharmaceutical and cosmetic products to both private and public-sector clients, including pharmacies, hospitals, and healthcare institutions.
INVESTING.COM
Financial Overview:
Revenue: In 2023, Ibnsina Pharma reported revenues of approximately EGP 33.95 billion.
BARRONS.COM
Net Income: The net income for the same period was EGP 173.14 million, resulting in a net profit margin of 0.51%.
BARRONS.COM
Total Assets and Liabilities: The company's total assets stood at EGP 18.55 billion, with total liabilities amounting to EGP 17.1 billion, indicating a debt-to-assets ratio of 92.19%.
BARRONS.COM
Shareholder Structure:
Ibnsina Pharma's ownership is diversified among prominent entities:
Free Float: 40.7%
Abdel Gawad Family: 15.0%
Faisal Islamic Bank: 14.0%
Mahgoub Family: 12.9%
European Bank for Reconstruction and Development (EBRD): 9.6%
Blom Investment: 7.8%
This diverse shareholder base has enhanced the company's corporate governance practices.
IR.IBNSINA-PHARMA.COM
Stock Performance:
As of January 29, 2025, the stock closed at EGP 7.02 per share, with a 52-week range between EGP 2.14 and EGP 7.59.
IR.IBNSINA-PHARMA.COM
Considerations for Investors:
While Ibnsina Pharma has demonstrated significant revenue generation, its net profit margin is relatively low, and the company operates with a high debt-to-assets ratio. Potential investors should weigh these factors carefully and consider consulting with a financial advisor to determine if this investment aligns with their risk tolerance and financial objectives.
Trade closed: stop reached
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.